The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects

被引：181

作者：

Maeng S. ^{[1
]}

Zarate Jr. C.A. ^{[1
]}

机构：

[1] Bethesda, MD 20892

来源：

Current Psychiatry Reports | 2007年 / 9卷 / 6期

基金：

美国国家卫生研究院;

关键词：

NMDA; Ketamine; NMDA Receptor; Mood Disorder; Memantine;

D O I：

10.1007/s11920-007-0063-1

中图分类号：

学科分类号：

摘要：

In this article, we first review a study showing that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine leads to rapid, robust, and relatively sustained antidepressant effects in patients with treatment-resistant major depression. We then discuss our hypothesis that the therapeutic effects of monoaminergic antidepressants and ketamine may be mediated by increased AMPA-to-NMDA glutamate receptor throughput in critical neuronal circuits. We hypothesize that ketamine directly mediates this throughput, whereas monoaminergic antidepressants work indirectly and gradually; this may explain, in part, the lag of onset of several weeks to months that is observed with traditional antidepressants. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：467 / 474

页数：7

共 57 条

[41]

De Vry J., Jentzsch K.R., Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine, Behav Pharmacol, 14, pp. 229-235, (2003)

[42]

Maler J.M., Esselmann H., Wiltfang J., Et al., Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons, Brain Res, 1052, pp. 156-162, (2005)

[43]

Green S.M., Rothrock S.G., Harris T., Et al., Intravenous ketamine for pediatric sedation in the emergency department: Safety profile with 156 cases, Acad Emerg Med, 5, pp. 971-976, (1998)

[44]

Berman R.M., Cappiello A., Anand A., Et al., Antidepressant effects of ketamine in depressed patients, Biol Psychiatry, 47, pp. 351-354, (2000)

[45]

Zarate Jr C.A., Singh J.B., Carlson P.J., Et al., A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression, Arch Gen Psychiatry, 63, pp. 856-864, (2006)

[46]

Entsuah A.R., Huang H., Thase M.E., Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo, J Clin Psychiatry, 62, pp. 869-877, (2001)

[47]

Thase M.E., Haight B.R., Richard N., Et al., Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials, J Clin Psychiatry, 66, pp. 974-981, (2005)

[48]

Wirz-Justice A., Van den Hoofdakker R.H., Sleep deprivation in depression: What do we know, where do we go?, Biol Psychiatry, 46, pp. 445-453, (1999)

[49]

Husain M.M., Rush A.J., Fink M., Et al., Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): A Consortium for Research in ECT (CORE) report, J Clin Psychiatry, 65, pp. 485-491, (2004)

[50]

Marangell L.B., George M.S., Callahan A.M., Et al., Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients, Arch Gen Psychiatry, 54, pp. 214-222, (1997)

← 1 2 3 4 5 6 →